Page 63 - Boxed Warning News Today

Biogen Inc.: New Data at AAN 2021 from Across Biogens MS Portfolio Demonstrate Positive Impact of Treatment on People Living with Relapsing Multiple Sclerosis (natalizumab) can lead to meaningful improvements in mental and social health compared to Ocrevus (ocrelizumab) (diroximel fumarate) reinforce the treatments positive gastrointestinal tolerability profile Biogen advances leading research to help inform future patient management including new information on the clinical profile of exte...

Qelbree (viloxazine extended-release capsules) represents the first novel non-stimulant treatment for ADHD in a decade Supernus plans to make Qelbree available in the U.S. in 2Q 2021 ROCKVILLE, MD., April 2, 2021 -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA...

Share this article Share this article INDIANAPOLIS, April 8, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today results of COV-BARRIER, a Phase 3 study evaluating baricitinib 4 mg once daily plus standard of care (SoC) versus placebo plus SoC. The trial did not meet statistical significance on the primary endpoint, which was defined as a difference in the proportion of participants progressing to the first occurrence of non-invasive ventilation incl...

FDA Approves Gileads Trodelvy To Treat Metastatic Triple-Negative Breast Cancer FOSTER CITY (dpa-AFX) - Gilead Sciences Inc. (GILD) said that the U.S. Food and Drug Administration has granted full approval to Trodelvy or sacituzumab govitecan-hziy for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer or TNBC who have received two or more prior systemic therapies, at least one of them for metastatic disease. Trodelvy significantly reduced the risk of d...

Message : Required fields TYSABRI is a well-established high-efficacy treatment that now provides two routes of administration enabling flexibility to meet patients individual preferences and needs The subcutaneous option provides a shorter administration time and expands access to treatment for patients and physicians beyond the infusion setting The approval adds to Biogen’s strong MS portfolio and is part of its leading, innovative work to improve the understanding of optimal clinical outc...

(0) TYSABRI is a well-established high-efficacy treatment that now provides two routes of administration enabling flexibility to meet patients individual preferences and needs The subcutaneous option provides a shorter administration time and expands access to treatment for patients and physicians beyond the infusion setting The approval adds to Biogens strong MS portfolio and is part of its leading, innovative work to improve the understanding of optimal clinical outcomes as part of the long-...

Lilly and Incyte communicate review extension of supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis News provided by Share this article Incyte logo. (PRNewsfoto/Eli Lilly and Company) INDIANAPOLIS, April 6, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for baric...

Search jobs 04-Mar-2021 Genentech’s Actemra Becomes the First Biologic Therapy Approved by the FDA for Slowing the Rate of Decline in Pulmonary Function in Adults With Systemic Sclerosis-Associated Interstitial Lung Disease, a Rare, Debilitating Condition – Systemic sclerosis (SSc) is a rare disease that impacts up to 75,000 people in the United States – – Approximately 80% of SSc patients may be affected by interstitial lung disease (ILD), a...

Eli Lilly and Company logo. (PRNewsfoto/Eli Lilly and Company) INDIANAPOLIS, March 3, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today top-line results from BRAVE-AA2, a Phase 3 study evaluating the efficacy and safety of once-daily baricitinib 2-mg and 4-mg in adults with severe alopecia areata (AA). Both doses of baricitinib met the primary efficacy endpoint at Week 36, demonstrating a statistically significant improvement in scalp hair regro...

The Atlantic What Americans Don’t Know About Their Medications People who have faced debilitating side effects say we need better warnings on drugs. The FDA hasn’t been enthusiastic. The Atlantic A few days ago, an unusual offer landed in my inbox. “Do you want to interview this man before he ends his life?” read the subject line of the message sent by Linda Martin, who, out of concerns for her safety, would tell me only that she is in her 60s and lives on the West Coast. She said that ...